Amgen unveils positive data from Phase 3 '482 study

Amgen recently reported positive data from the Phase 3 '482 study, which is the largest international multiple myeloma trial ever conducted.
The company noted in a press release that XGEVA met the primary endpoint for the study; it showed non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. Amgen plans to release this information at the 16th International Myeloma Workshop in New Delhi during the event’s late-breaking abstract session.
"Bone complications are devastating for patients with multiple myeloma. Renal function is a constant consideration in the treatment of multiple myeloma patients, often preventing the use of bisphosphonates, the only approved class of agents for prevention of bone complications, underscoring the need for new treatment options," Dr. Noopur Raje, director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center in Boston, said in a statement. "The results of this study showed that denosumab may be an effective novel option that is not cleared through the kidneys that may help prevent bone complications in patients with multiple myeloma."
Multiple myeloma, the second-most common hematologic cancer, develops within plasma cells in bone marrow.